Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma cytologically or histologically proved or diagnosed according the criteria of the American Association for the Study of Liver Diseases(AASLD 2005)~* Three nodules maximum (unilobar disease without limitation in the number of nodules; 3 maximum nodules if bilobar disease \[satellite nodules \<1cm not included in the total sum\])~* Child-Pugh score A or B7~* ECOG Performance Status \< 2~* Platelet count \> 50,000/µl and absolute neutrophil count (ANC) \>1,000/µl~* Serum creatinine \< 150 µmol/l~* Resting ejection fraction \> 50% (echocardiography or isotopic method)~* Age \> 18 years~* Signed written informed consent~Exclusion Criteria:~* Patients eligible for surgical resection or hepatic transplantation or radiofrequency ablation~* Extrahepatic metastases~* Known gastrointestinal bleeding up to 30 days before study entry~* Patients with anticoagulant treatment~* Evidence of portal vein thrombosis~* Pregnancy~* Clinically serious infection~* Known hypersensitivity to anthracyclines~* Known hypersensitivity to contrast medium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idarubicin (Type: EXPERIMENTAL): Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg

Based on this trial design, predict the completion outcome and termination type (if applicable).